Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Inclusion Criteria: Metastatic pancreatic carcinoma (excluding pancreatic endocrine tumors); histologic confirmation of either the primary or metastatic site. ECOG performance status of < 1 > 4 weeks since completion of previous chemotherapy > 4 weeks since participation in any investigational drug study Peripheral neuropathy of grade < 1 Patients must have failed a gemcitabine-containing regimen administered in the metastatic, adjuvant, or locally advanced setting. Absolute neutrophil count (ANC) > 1,500/mm3 Hemoglobin > 9.0gm/dl Platelets > 100,000/mm3 Total bilirubin < 2.0mg/dl AST and alkaline phosphatase < 5 x upper limit of normal (ULN) Albumin > 2.5gm/dl CA 19-9 > 1.5 x ULN Exclusion Criteria: Prior therapy with taxane or with epidermal growth factor receptor (EGFR) inhibitors More than one prior chemotherapy treatment Clinically significant cardiac disease Major surgery within 4 weeks of the start of study treatment Evidence of central nervous system (CNS) metastases or carcinomatous meningitis or history of uncontrolled seizures, central nervous system disorders. Uncontrolled serious medical or psychiatric illness Pregnant or breast-feeding women Other active malignancy Inability to swallow tablets or evidence of a gastrointestinal malabsorption syndrome Known severe hypersensitivity to Iressa Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St. John's wort. History of severe hypersensitivity reaction to drugs formulated with polysorbate 80 Any evidence of clinically active interstitial lung disease Ascites requiring paracentesis